Antisense Therapeutics seeks ethics approval for stem cell mobilisation trial – Proactive Investors Australia
| Proactive Investors Australia Antisense Therapeutics (ASX:ANP) is applying for ethics approval to conduct a Phase 1 proof of concept trial of its ATL1102 technology to mobilise stem cells from bone marrow into blood. Mobilising stem cells in this manner is used to improve outcomes … |
